Dokumentdetails
ID
doi:10.1186/s12866-023-03166-4...
Autor
Pourali, Ghazaleh Kazemi, Danial Chadeganipour, Amir Shayan Arastonejad, Mahshid Kashani, Sara Naghizadeh Pourali, Roozbeh Maftooh, Mina Akbarzade, Hamed Fiuji, Hamid Hassanian, Seyed Mahdi Ghayour-Mobarhan, Majid Ferns, Gordon A. Khazaei, Majid Avan, AmirLangue
enEditor
BioMed Central
Kategorie
Mycology
Jahr
2024
Auflistungsdatum
10.01.2024
Schlüsselwörter
microbiome pancreatic cancer biomarker treatment probiotics diagnosis prognosis cancer microbiome pcZusammenfassung
Studying the effects of the microbiome on the development of different types of cancer has recently received increasing research attention.
In this context, the microbial content of organs of the gastrointestinal tract has been proposed to play a potential role in the development of pancreatic cancer (PC).
Proposed mechanisms for the pathogenesis of PC include persistent inflammation caused by microbiota leading to an impairment of antitumor immune surveillance and altered cellular processes in the tumor microenvironment.
The limited available diagnostic markers that can currently be used for screening suggest the importance of microbial composition as a non-invasive biomarker that can be used in clinical settings.
Samples including saliva, stool, and blood can be analyzed by 16 s rRNA sequencing to determine the relative abundance of specific bacteria.
Studies have shown the potentially beneficial effects of prebiotics, probiotics, antibiotics, fecal microbial transplantation, and bacteriophage therapy in altering microbial diversity, and subsequently improving treatment outcomes.
In this review, we summarize the potential impact of the microbiome in the pathogenesis of PC, and the role these microorganisms might play as biomarkers in the diagnosis and determining the prognosis of patients.
We also discuss novel treatment methods being used to minimize or prevent the progression of dysbiosis by modulating the microbial composition.
Emerging evidence is supportive of applying these findings to improve current therapeutic strategies employed in the treatment of PC.
Pourali, Ghazaleh,Kazemi, Danial,Chadeganipour, Amir Shayan,Arastonejad, Mahshid,Kashani, Sara Naghizadeh,Pourali, Roozbeh,Maftooh, Mina,Akbarzade, Hamed,Fiuji, Hamid,Hassanian, Seyed Mahdi,Ghayour-Mobarhan, Majid,Ferns, Gordon A.,Khazaei, Majid,Avan, Amir, 2024, Microbiome as a biomarker and therapeutic target in pancreatic cancer, BioMed Central
Configurable Safety Tuning of Language Models with Synthetic Preference Data
data preference cst dpo configurable language safety
Affective flexibility as a developmental building block of cognitive reappraisal: An fMRI study
cognitive success affective flexibility
